Biosimilar Newsletter Archive

1. 12.13.18 -- How Will Trump's FTC/DOJ Reporting Requirement Impact Biosimilars?
   12/13/2018
   12/13/18 Biosimilar Development Newsletter
2. 12.08.18 -- Biosimilars Vs. AbbVie: Humirapocalypse Or Growing Pains?
   12/8/2018
   12/08/18 Biosimilar Development Newsletter
3. 12.06.18 -- U.S. Biosimilar Progress: How Should We Really Feel?
   12/6/2018
   12/06/18 Biosimilar Development Newsletter
4. 12.04.18 -- Considerations In API Scale Up Strategy
   12/4/2018
   12/04/18 Biosimilar Development Newsletter
5. 11.29.18 -- Mylan's Pegfilgrastim: Retracing Its Fulphila Journey
   11/29/2018
   11/29/18 Biosimilar Development Newsletter
6. 11.27.18 -- How Automation Accelerates Biosimilar Manufacturing With Flexibility And Efficiency
   11/27/2018
   11/27/18 Biosimilar Development Newsletter
7. 11.21.18 -- Where Do Employers Stand With Biosimilars?
   11/21/2018
   11/21/18 Biosimilar Development Newsletter
8. 11.15.18 -- Biosimilars Vs. AbbVie: "Humirapocalypse" Or Illusion?
   11/15/2018
   11/15/18 Biosimilar Development Newsletter
9. 11.14.18 -- Business Strategies That Can Help Speed New Therapeutic Modalities To Market
   11/14/2018
   11/14/18 Biosimilar Development Newsletter
10. 11.08.18 -- Biosimilars, Biobetters, Or Both?: Manufacturing Considerations
    11/8/2018
    11/08/18 Biosimilar Development Newsletter